At the Healthcare Analytics Summit™ 2024 (HAS® 24), Jennifer Doudna, PhD, of the University of California, Berkeley, sat down with Melissa Welch, MD, MPH, President of Welch Perspectives Healthcare ...
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...
Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...
Researchers announced three distinct CRISPR developments: a diagnostic test that distinguishes multiple viruses by reaction speed, early trial results for an autoimmune cell therapy, and laboratory ...
Intellia also separately announced positive topline data today from the Phase 3 HAELO clinical trial of lonvo-z in HAE. The trial met its primary and all key secondary endpoints, demonstrating that a ...
Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...
Following its FDA-approved Casgevy therapy for sickle cell disease and beta thalassemia, CRISPR technology is now being tested in autoimmune disorders and early Down syndrome studies. CRISPR ...
Researchers at Gladstone Institutes (CA, USA) have mapped the human immune response using next-generation CRISPR technology known as base editing. Using this tool, the team was able to identify ...
CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results